# US 2023/0404932 A1 · Method for treating blastocystis infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404932 A1
- Document ID: US20230404932A1
- Status: Published application
- Kind: A1
- Application number: 18/193,692
- Filed: 2023-03-31
- Published: 2023-12-21
- Earliest claimed: 2022-06-17
- Assignees: Imam Abdulrahman Bin Faisal University
- Applicants: Imam Abdulrahman Bin Faisal University
- Inventors: B. Rabindran JERMY; Vijaya RAVINAYAGAM; Ayman A. ELBADRY
- Web page: https://patentgrep.com/patent/US20230404932A1

## CPC

- A61K 9/5115: {Inorganic compounds}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/12: Ketones
- A61P 33/00: Antiparasitic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 19)

The method of claim 19, wherein the porous silicate and/or aluminosilicate matrix is at least one selected from the group consisting of MCM-41 and KIT-6.

### Claim 3 (depends on 2)

The method of claim 2, wherein the nanocarrier has a surface area of 225 to 750 m2/g, a pore volume of 0.25 to 0.85 cm3/g, and a mean pore size of 2 to 10 nm.

### Claim 4 (depends on 2)

The method of claim 2, wherein the porous silicate and/or aluminosilicate matrix is MCM-41 and the nanocarrier has a surface area of 450 to 750 m2/g, a pore volume of 0.25 to 0.65 cm3/g, and a mean pore size of 2 to 4 nm.

### Claim 5 (depends on 2)

The method of claim 2, wherein the porous silicate and/or aluminosilicate matrix is KIT-6 and the nanocarrier has a surface area of 225 to 450 m2/g, a pore volume of 0.45 to 0.85 cm3/g, and a mean pore size of 5 to 10 nm.

### Claim 6 (depends on 19)

The method of claim 19, wherein the porous silicate and/or aluminosilicate matrix is present in an amount of 1 to 20 wt % based on a total weight of the nanocarrier.

### Claim 7 (depends on 19)

The method of claim 19, wherein the metal organic framework comprises an imidazole of formula I:
and is substantially free of a benzimidazole of formula II:

### Claim 8 (depends on 7)

The method of claim 7, wherein the zeolitic imidazolate framework is ZIF-8.

### Claim 9 (depends on 19)

The method of claim 19, wherein the antioxidant is at least one selected from the group consisting of quercetin, rutin, coenzyme Q10, gallic acid, resveratrol, and curcumin.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antioxidant is curcumin.

### Claim 11 (depends on 9)

The method of claim 9, wherein the antioxidant is resveratrol.

### Claim 12 (depends on 19)

The method of claim 19, wherein the antioxidant is present in the nanomedicinal composition in an amount of 5 to 50 wt %, based on a total weight of nanomedicinal composition.

### Claim 13 (depends on 10)

The method of claim 10, wherein the nanomedicinal composition releases greater than 20% of a total weight of curcumin within 24 to 72 hours of contact with a suitable biological medium.

### Claim 14 (depends on 11)

The method of claim 11, wherein the nanomedicinal composition releases greater than 7.5% of a total weight of resveratrol within 24 to 72 hours of contact with a suitable biological medium.

### Claim 15 (depends on 19)

The method of claim 19, wherein the nanomedicinal composition reduces the viability of Blastocystis organisms by at least 75% when the nanomedicinal composition is present for 24 hours in an amount of 100 to 1000 μg/mL.

### Claim at position 16

16-18. (canceled)

### Claim 19

A method for treating an infection by a parasite in the genus Blastocystis in a subject, comprising:
administering a pharmaceutical composition comprising a nanomedicinal composition to the subject in need of treatment for a Blastocystis infection,
wherein the nanomedicinal composition comprises a nanocarrier comprising:
a metal organic framework which is a zeolitic imidazolate framework, and
a porous silicate and/or aluminosilicate matrix; and
an antioxidant disposed in the pores and/or on a surface of the nanocarrier.

### Claim 20

(canceled)
